Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) Overview | 7 | 1 |
| Therapeutics Development | 8 | 4 |
| Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) Products under Development by Stage of Development | 8 | 1 |
| Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) Products under Development by Therapy Area | 9 | 1 |
| Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) Products under Development by Indication | 10 | 2 |
| Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) Pipeline Products Glance | 12 | 2 |
| Late Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) Products under Development by Companies | 14 | 2 |
| Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) Products under Development by Universities/Institutes | 16 | 2 |
| Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) Therapeutics Assessment | 18 | 7 |
| Assessment by Monotherapy/Combination Products | 18 | 1 |
| Assessment by Mechanism of Action | 19 | 2 |
| Assessment by Route of Administration | 21 | 2 |
| Assessment by Molecule Type | 23 | 2 |
| Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) Companies Involved in Therapeutics Development | 25 | 4 |
| Cleveland BioLabs, Inc. | 25 | 1 |
| Neuropore Therapies, Inc. | 26 | 1 |
| Opsona Therapeutics Limited | 27 | 1 |
| Vascular Biogenics Ltd. | 28 | 1 |
| Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) Drug Profiles | 29 | 22 |
| CBLB-612 Drug Profile | 29 | 2 |
| CBLB-613 Drug Profile | 31 | 1 |
| DMT-200 Drug Profile | 32 | 2 |
| DMT-210 Drug Profile | 34 | 1 |
| DMT-220 Drug Profile | 35 | 1 |
| infectious vaccine Drug Profile | 36 | 1 |
| OPN-305 Drug Profile | 37 | 2 |
| P-13 Drug Profile | 39 | 1 |
| P-MAPA Drug Profile | 40 | 2 |
| Small Molecules to Agonize TLR2 for Neurodegenerative Diseases Drug Profile | 42 | 1 |
| Small Molecules to Antagonize TLR-1 and TLR-2 for Infectious Disease and Neuroinflammation Drug Profile | 43 | 1 |
| Small Molecules to Antagonize TLR2 and TLR4 for Immune inflammatory Diseases Drug Profile | 44 | 1 |
| SP-16 Drug Profile | 45 | 1 |
| Synthetic Peptide to Target PPAR-Gamma and TLR-2 and IBD and Tissue Injury Drug Profile | 46 | 1 |
| Vaccine to Target MUC-1 and TLR-2 for Breast Cancer Drug Profile | 47 | 1 |
| VB-201 Drug Profile | 48 | 3 |
| Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) Dormant Projects | 51 | 3 |
| Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) Discontinued Products | 54 | 1 |
| Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) Featured News &Press Releases | 55 | 9 |
| May 16, 2016: Dermata Therapeutics Announces Initiation of Phase 1 Pharmacokinetic Study | 55 | 1 |
| Jan 26, 2016: Cleveland BioLabs Announces Start of Phase 2 Study of CBLB612 in Russian Federation | 55 | 1 |
| Jul 13, 2015: Cleveland BioLabs Announces Results of Phase 1 Study of CBLB612 in Russian Federation | 56 | 1 |
| Apr 02, 2015: Cleveland BioLabs Announces New U.S. Composition of Matter Patent for CBLB612 | 56 | 1 |
| Mar 16, 2015: Cleveland BioLabs Announces Completion of Dosing in Phase 1 Study of CBLB612 in Russian Federation | 57 | 1 |
| Mar 02, 2015: Opsona Therapeutics commences Part B of phase II study of Blocking Toll-Like Receptor 2 in Extended Criteria Donor renal transplant recipients at high risk of Early Graft Dysfunction | 57 | 1 |
| Feb 23, 2015: Opsona Therapeutics Patent issued in USA covering an antibody directed against Toll-like Receptor-2 (TLR-2) and the use and development thereof | 57 | 1 |
| Feb 18, 2015: Opsona Therapeutics Patent issued in US and EU covering the Opsona-developed antibody OPN-305, which is directed against Toll-like Receptor-2 (TLR-2) and the use and development thereof | 58 | 1 |
| Feb 17, 2015: VBL Therapeutics Reports Topline Results From Phase 2 Studies of VB-201 in Psoriasis and Ulcerative Colitis | 59 | 1 |
| Feb 09, 2015: VBL Therapeutics to Present Preclinical Data at Keystone Symposium on Liver Metabolism and Nonalcoholic Fatty Liver Disease | 60 | 1 |
| Feb 06, 2015: VBL Therapeutics Receives European Patent Issuance on Lecinoxoid Platform Technology | 61 | 1 |
| Jan 29, 2015: VBL Therapeutic In Cooperation With KCR Reported LPO In Phase 2 Of VB-201 | 61 | 1 |
| Jan 27, 2015: Opsona Therapeutics initiates phase I / II prospective open in patients with myelodysplastic syndrome second line of lower level (low and intermediate-1) with OPN-305 label ... | 62 | 1 |
| Jan 27, 2015: Opsona Therapeutics OPN-305 examines pretreatment myelodysplasia | 62 | 1 |
| Jan 26, 2015: Opsona Therapeutics initiates a prospective open label Phase I/II study in second-line lower (Low and intermediate-1) risk myelodysplastic syndrome (MDS) with OPN-305, a First-in Class Monoclonal | 62 | 2 |
| Appendix | 64 | 2 |
| Methodology | 64 | 1 |
| Coverage | 64 | 1 |
| Secondary Research | 64 | 1 |
| Primary Research | 64 | 1 |
| Expert Panel Validation | 64 | 1 |
| Contact Us | 64 | 1 |
| Disclaimer | 65 | 1 |